Tyche Wealth Partners LLC Has $1.18 Million Stock Position in Stryker Co. (NYSE:SYK)

Tyche Wealth Partners LLC raised its position in shares of Stryker Co. (NYSE:SYK) by 191.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,280 shares of the medical technology company’s stock after buying an additional 2,154 shares during the quarter. Tyche Wealth Partners LLC’s holdings in Stryker were worth $1,181,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Dunhill Financial LLC boosted its stake in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares during the period. Darwin Wealth Management LLC bought a new position in Stryker during the third quarter valued at approximately $36,000. Crews Bank & Trust acquired a new stake in shares of Stryker in the 4th quarter valued at $39,000. Hara Capital LLC bought a new stake in shares of Stryker during the 3rd quarter worth about $42,000. Finally, Grove Bank & Trust increased its holdings in shares of Stryker by 84.8% during the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock valued at $44,000 after acquiring an additional 56 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.50% of the stock is owned by insiders.

Stryker Stock Up 1.7 %

SYK stock opened at $399.01 on Thursday. The business has a 50-day moving average of $376.87 and a 200-day moving average of $364.00. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The stock has a market capitalization of $152.11 billion, a P/E ratio of 51.42, a P/E/G ratio of 2.78 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 EPS. On average, sell-side analysts anticipate that Stryker Co. will post 13.5 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.84%. Stryker’s dividend payout ratio is presently 43.30%.

Wall Street Analysts Forecast Growth

SYK has been the subject of several research reports. JPMorgan Chase & Co. increased their price objective on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Royal Bank of Canada boosted their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. JMP Securities reissued a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Finally, The Goldman Sachs Group boosted their price objective on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $419.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.